Evaxion Biotech has reported three-year data for EVX-01, its AI-designed therapeutic vaccine candidate for melanoma, extending the follow-up window on a program the Danish company has positioned as a personalized off-the-shelf-style answer to post-surgical relapse in advanced disease.

The disclosure, surfaced via Investing.com on June 11, is a data longevity update rather than a new pivotal readout — and for a field where durable responses are the whole game, that distinction matters. Three years of follow-up is the metric oncology investors and melanoma specialists watch most closely, because late recurrence, not initial response, is what has stalled earlier therapeutic vaccine attempts.

What is EVX-01, exactly?

EVX-01 is a personalized therapeutic cancer vaccine built on Evaxion's proprietary AI platform, which computationally selects neoantigen targets from an individual patient's tumor. The candidate is designed for patients with melanoma — the skin cancer where therapeutic vaccination has gained the most clinical traction, and where adjuvant treatment after resection remains a competitive, checkpoint-inhibitor-dominated space.

The company has not disclosed detailed efficacy figures in the headline announcement itself; the full dataset sits behind the original release. What the announcement establishes is the milestone itself: Evaxion has reached the three-year follow-up mark and is publishing on it.

Why three-year follow-up carries weight in melanoma

Melanoma recurrence patterns justify the attention. A meaningful share of high-risk patients who undergo complete resection relapse within the first two to three years, which is precisely why regulatory endpoints in adjuvant melanoma trials — recurrence-free survival and distant metastasis-free survival — are tracked over multi-year horizons rather than months.

For a neoantigen vaccine, three-year data answers two questions at once. First, did any immune-driven benefit persist after the vaccination course ended? Second, did the approach show a safety profile that holds up over cumulative years rather than a single treatment cycle? Evaxion's decision to report at this timepoint signals the company believes it has something durable to show on both counts.

It also keeps Evaxion in a conversation that has gotten crowded. Moderna and Merck's mRNA-4157 (V940) partnered program has drawn the bulk of attention in personalized melanoma vaccination, leaving smaller players like Evaxion under pressure to demonstrate that alternative neoantigen-selection platforms can deliver comparable staying power.

What does this change for dermatology and oncology practice?

Right now, nothing on the prescribing side. EVX-01 remains an investigational candidate, not an approved therapy, so the practical impact lands on trial investigators, referring dermatologists who counsel high-risk melanoma patients on research options, and the investors who fund the platform.

For dermatologists, the relevant takeaway is direction of travel: therapeutic vaccination in melanoma continues to accumulate multi-year datasets, which strengthens the case for discussing clinical-trial enrollment with resected stage IIB–IV patients who ask what's coming beyond anti-PD-1 therapy. For Evaxion, the three-year report is a credibility checkpoint — proof the platform can keep producing publishable follow-up rather than fading after early-phase headlines.

The next concrete step to watch is whether Evaxion pairs this follow-up dataset with a named later-stage development path, including a partner and a registrational timeline. Until then, the three-year mark stands as the story: a small AI-driven vaccine program still alive, still reporting, three years in.